<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Improved COVID-19 Testing by Rapid Sample Purification</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>12/15/2020</AwardEffectiveDate>
<AwardExpirationDate>08/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>256000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improved reliability for coronavirus detection. The proposed project will develop a tissue purification technology to extract (purify) virus from patient samples. Purer samples (more coronavirus, less confounding materials) is anticipated to improve signal from virus and reduce signal from non-virus materials, and is therefore anticipated to improve the reliability of testing (fewer false positives and false negatives). This can potentially impact the social distancing of the pandemic. &lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project of a system to extract purified samples for coronavirus testing for downstream testing, such as PCR-based analysis. The system is a novel purification technology that uses biological (antibodies) and other physical to quickly and reliably extract target microorganisms (here COVID viruses) from human samples.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>12/21/2020</MinAmdLetterDate>
<MaxAmdLetterDate>05/18/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2036463</AwardID>
<Investigator>
<FirstName>Benjamin</FirstName>
<LastName>Shapiro</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Benjamin Shapiro</PI_FULL_NAME>
<EmailAddress>Ben@xMDDiagnostics.com</EmailAddress>
<PI_PHON>3014556502</PI_PHON>
<NSF_ID>000828952</NSF_ID>
<StartDate>12/21/2020</StartDate>
<EndDate>05/18/2021</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Ting-Pau</FirstName>
<LastName>Oei</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Ting-Pau Oei</PI_FULL_NAME>
<EmailAddress>tingpau@xmddiagnostics.com</EmailAddress>
<PI_PHON>6466626669</PI_PHON>
<NSF_ID>000839099</NSF_ID>
<StartDate>05/18/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>XMD DIAGNOSTICS, LLC</Name>
<CityName>BALTIMORE</CityName>
<CountyName/>
<ZipCode>212155216</ZipCode>
<PhoneNumber>6466626669</PhoneNumber>
<StreetAddress>2401 W BELVEDERE AVE. SCHAPIRO B</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Maryland</StateName>
<StateCode>MD</StateCode>
<CONGRESSDISTRICT>90</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MD90</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080588182</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>XMD DIAGNOSTICS, LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[XMD DIAGNOSTICS, LLC]]></Name>
<CityName>Baltimore</CityName>
<CountyName/>
<StateCode>MD</StateCode>
<ZipCode>212155216</ZipCode>
<StreetAddress><![CDATA[2401 W BELVEDERE AVE., SCHAPIRO]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Maryland</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>07</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MD07</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>004E</Code>
<Text>BIOMEDICAL ENG AND DIAGNOSTICS</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~256000</FUND_OBLG>
</Award>
</rootTag>
